Tags: Valeant | CEO | Allergan | Poison Pill

Valeant CEO 'Disappointed' In Allergan Poison Pill: CNBC

Wednesday, 23 Apr 2014 09:47 AM

The chief executive officer of Valeant Pharmaceuticals, which made a $47 billion unsolicited offer for competitor Allergan Inc. on Tuesday, said during an interview on CNBC that he was "disappointed" with Allergan's so-called poison pill.

Allergan on Tuesday night said that its board of directors had adopted a one-year stockholder rights plan to give it more time to consider takeover proposals. The Valeant offer was made with Pershing Square Capital Management hedge fund, which built up a stake in the company.

"We are disappointed but on the other hand, I think this deal will get done," Valeant CEO Michael Pearson said on Wednesday.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
StreetTalk
The chief executive officer of Valeant Pharmaceuticals, which made a $47 billion unsolicited offer for competitor Allergan Inc. on Tuesday, said during an interview on CNBC that he was disappointed with Allergan's so-called poison pill.
Valeant, CEO, Allergan, Poison Pill
103
2014-47-23
Wednesday, 23 Apr 2014 09:47 AM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved